These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Suto A; Bradlow HL; Wong GY; Osborne MP; Telang NT Breast Cancer Res Treat; 1993 Sep; 27(3):193-202. PubMed ID: 8312577 [TBL] [Abstract][Full Text] [Related]
5. Effect of tamoxifen on mammary preneoplasia: relevance to chemopreventive intervention. Telang NT; Bradlow HL; Osborne MP Cancer Detect Prev; 1994; 18(4):313-21. PubMed ID: 7982241 [TBL] [Abstract][Full Text] [Related]
6. Indole-3-carbinol. A novel approach to breast cancer prevention. Bradlow HL; Sepkovic DW; Telang NT; Osborne MP Ann N Y Acad Sci; 1995 Sep; 768():180-200. PubMed ID: 8526347 [TBL] [Abstract][Full Text] [Related]
7. Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Abba MC; Hu Y; Levy CC; Gaddis S; Kittrell FS; Hill J; Bissonnette RP; Brown PH; Medina D; Aldaz CM Cancer Prev Res (Phila); 2009 Feb; 2(2):175-84. PubMed ID: 19174580 [TBL] [Abstract][Full Text] [Related]
8. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Fabian CJ; Kimler BF Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443 [TBL] [Abstract][Full Text] [Related]
9. 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland. Green A; Shilkaitis A; Christov K Carcinogenesis; 1999 Aug; 20(8):1535-40. PubMed ID: 10426803 [TBL] [Abstract][Full Text] [Related]
10. Early pathologic changes in experimental and human breast cancer: facts and comments. Squartini F; Bistocchi M; Sarnelli R; Basolo F Ann N Y Acad Sci; 1986; 464():231-61. PubMed ID: 3014948 [No Abstract] [Full Text] [Related]
11. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. Dhingra K J Cell Biochem Suppl; 1995; 23():19-24. PubMed ID: 8747374 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Katdare M; Osborne MP; Telang NT Oncol Rep; 1998; 5(2):311-5. PubMed ID: 9468547 [TBL] [Abstract][Full Text] [Related]
14. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. Mehta RG; Williamson E; Patel MK; Koeffler HP J Natl Cancer Inst; 2000 Mar; 92(5):418-23. PubMed ID: 10699072 [TBL] [Abstract][Full Text] [Related]
15. Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Telang NT; Katdare M; Bradlow HL; Osborne MP Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):559-64. PubMed ID: 9167995 [TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of mammary preneoplasia. In vitro effects of a green tea polyphenol. Araki R; Inoue S; Osborne MP; Telang NT Ann N Y Acad Sci; 1995 Sep; 768():215-22. PubMed ID: 8526351 [TBL] [Abstract][Full Text] [Related]